Pharmaco - Press Releases

Date	Title	Company
02-Jun-2020	UCB and N-SIDE increase their strategic collaboration	Sciad Newswire
02-Jun-2020	RAPID NUTRITION PLC: Delivers Latest Market Update with Focus on New Innovative Products and International Growth	RAPID NUTRITION PLC
01-Jun-2020	Coronavirus (COVID-19) Update: Daily Roundup	U.S. Food and Drug Administration
01-Jun-2020	APhA Swears in Scott J. Knoer as its 13th Chief Executive Officer	American Pharmacists Association
01-Jun-2020	Natera Launches Quantification Technique to Enhance Prospera(TM) Test Precision; Initiates PEDAL Study for New Insights	Natera, Inc.
01-Jun-2020	San Diego Top Doctor Collaborates with Therapeutic Solutions International to Report QuadraMune(TM) Immune Boosting Data in Clinical Trial	Therapeutic Solutions International, Inc.
01-Jun-2020	CytRx Corporation Highlights Orphazyme's Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C	CytRx Corporation
01-Jun-2020	White Paper for Investors and Lenders Highlights Risks of Excess Assets in Biopharmaceutical Sector	Tiger Group
01-Jun-2020	Publication in Nature Communications Highlights the Preclinical Development of SYNB1891 and its Potential as a Dual Innate Immune Activator to Stimulate an Immune Response in Difficult to Treat Tumors	Synlogic, Inc.
01-Jun-2020	Henlius and Accord Receive Positive CHMP Opinion for Oncology Biosimilar, HLX02 (Trastuzumab)	Henlius
01-Jun-2020	AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors	AbbVie
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT® (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT(R) (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT(R) (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT(R) (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma	Innovent Biologics, Inc.
31-May-2020	Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)	Innovent Biologics, Inc.
31-May-2020	BioMarin Provides Highlights of 4 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A	BioMarin Pharmaceutical Inc.